{"id":"W4396863343","doi":"10.1177/17588359241250158","title":"Clinical activity of pembrolizumab in refractory <i>MDM2</i> -amplified advanced intimal sarcomas","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech; Deciphera Pharmaceuticals; Iterion Therapeutics; Karyopharm Therapeutics; Amgen; Pfizer; Daiichi Sankyo Europe; Bristol-Myers Squibb; Symphogen; GlaxoSmithKline","keywords":"Pembrolizumab; Medicine; Sarcoma; Tumor microenvironment; Refractory (planetary science); Oncology; Soft tissue sarcoma; Internal medicine; Immunotherapy; Chemotherapy; Pathology; Cancer research; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001194578,0.0002479876,0.001150493,0.0002664883,0.00002002913,0.000004724247,0.0002137676,0.0004454834,0.0005219734],"category_scores_gemma":[0.0004104513,0.0001891582,0.0002072375,0.0004789761,0.0006172464,0.0001755749,0.00009084567,0.001126745,0.00003556554],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004330081,"about_ca_system_score_gemma":0.0008484734,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003029574,"about_ca_topic_score_gemma":0.0002120683,"domain_scores_codex":[0.9969711,0.0004684546,0.0009710197,0.000570951,0.0005582084,0.0004602786],"domain_scores_gemma":[0.9961456,0.003067826,0.0001401312,0.0003653329,0.00004313413,0.0002379403],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002065912,0.003564093,0.05004411,0.0001712543,0.00009100193,0.00175412,0.0001645027,0.000007661745,0.0002936526,0.001853131,0.00003910562,0.9399515],"study_design_scores_gemma":[0.01986151,0.006338505,0.2786549,0.001727599,0.0002420397,0.000455463,0.0002803834,0.002154665,0.0009624403,0.007115459,0.6817614,0.000445544],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9010558,0.08235445,0.0005776228,0.005567127,0.001276613,0.0006607918,0.000006320172,0.00009158858,0.008409702],"genre_scores_gemma":[0.972438,0.02440339,0.001015966,0.001736473,0.0001886174,0.0001257436,0.000008716385,0.00003219648,0.00005089199],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9395059,"threshold_uncertainty_score":0.7713648,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04223307785315796,"score_gpt":0.4423355491676195,"score_spread":0.4001024713144615,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}